Skip to main content
DRMTY logo

Dr. Martens plc (DRMTY) Stock Price & Analysis

Dr. Martens plc (DRMTY) — price $1.40 (0.00%), as of the Nov 19, 2026 trading session; market cap $665M.

Educational signal · not a buy or sell recommendation · How to read this

$1.40 $0.00 (0.00%) Market Cap $665M

Dr. Martens plc · DRMTY

Dr. Martens plc designs, develops, and distributes footwear globally, operating under the iconic Dr. Martens brand. The company's product range includes originals, fusion styles, kids' footwear, casual options, and accessories.

Price as of Nov 19, 2026

Key Statistics

Not scored: MoonshotScore covers actively traded US operating companies, not funds, preferred shares, warrants or thinly traded stocks.

Thousands of the 20,000+ US stocks here carry a MoonshotScore.

Scored companies in the same industry:

  • WEYS · Weyco Group, Inc. · 93 /100
  • WINA · Winmark Corporation · 93 /100
  • CAL · Caleres, Inc. · 72 /100

See all scored stocks →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$1.40
Change on the day0.00%
52-week range$1.36 – $2.47
Market capitalisation$665M—
Price / earnings (trailing)19.03
Shares traded on the day1.3K

Price & events

Other perspectives

Council score for Dr. Martens (DRMTY): perspectives

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Legends Council

5 lenses, 0 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Dalio-style lens (simulated) Ray Dalio Favorable read
Simons-style lens (simulated) Jim Simons Neutral read
Englander-style lens (simulated) Izzy Englander Favorable read
Klarman-style lens (simulated) Seth Klarman Favorable read
Moon AI lens (model) Neutral read

Read on: Nov 17, 2026 · older than the 27 hours refresh window; not a current reading

Munger's Mindset

Balance Sheet & Valuation · historical

Financial Health Neutral
Margin of Safety Undervalued
Profit Margin Weak
Revenue Growth Negative
Debt/Equity Negative
ROE Neutral
Gross Margin Moderate

Read on: Sep 11, 2026 · older than the 27 hours refresh window; not a current reading

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

On Sep 11, 2026, the Munger lens read the price at that time as undervalued against its own estimate of value.

Readings on this page are from Nov 20, 2026, except a card that shows its own read date.

1 · What is it?

What is Dr. Martens (DRMTY), and what does it report?

Short answer

A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Dr. Martens plc (DRMTY) is the company analyzed here. It employs 2,377 people and is led by Ije Nwokorie. In Q2 FY2027 it reported revenue of £292M and net income of -£6M. The market values it at $665M.

2 · Latest results

What do the latest results show for Dr. Martens (DRMTY)?

Short answer · as of

The most recent reported quarter, Q2 FY2027, carried revenue of £292M.

Quarterly income statement — 4 quarters
Revenue, net income and earnings per share by quarter
PeriodRevenueNet incomeEPS
Q2 FY2027£292M-£6M-£0.01 (diluted)
Q4 FY2026£450M£34M£0.07 (diluted)
Q2 FY2026£321M-£10M-£0.02 (diluted)
Q4 FY2025£463M£25M£0.07 (diluted)
3 · Financial strengths and risks

What are the financial strengths and risks for Dr. Martens (DRMTY)?

Short answer · as of

The distress and quality screens read Altman Z 4.80 · Piotroski F 6. Trailing ratios: ROE 8.1% · ROA 3.2% · current ratio 2.34 · earnings yield 5.4% · free-cash-flow yield 17.9%.

The records behind this page

Who holds the shares?

Institutional ownership reported through 13F filings.

Tracked investors

Which of the 16 named investors we follow held DRMTY in their latest 13F filing, and what they did against the filing before it.

None of the 16 tracked investors reported DRMTY in their latest 13F filing.

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

What has been published about Dr. Martens (DRMTY)?

Read these with our analysis →

Common Questions About DRMTY

These answers are editorial: 2 of these 8 answers are drawn from the DRMTY research dossier (written Mar 18, 2026 by gemini-2.0-flash); the other 6 are question templates that restate figures shown above. Figures in this section are not part of the source register.

Is DRMTY a good stock to buy?

Stock Expert AI does not rate DRMTY buy, sell or hold. Dr. Martens plc has no MoonshotScore yet; read the financial checkup, analyst consensus and risks directly. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.

What is the DRMTY stock price today?

The last price recorded for Dr. Martens plc (DRMTY), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

What does Dr. Martens plc do?

Dr. Martens plc designs, develops, procures, markets, sells, and distributes footwear globally. The company's product segments include originals, fusion, kids, and casual, as well as accessories. It operates under the Dr. Martens brand name, selling through owned retail stores, e-commerce platforms, and wholesale partners.

What are the main risks for DRMTY?

The main risks for DRMTY include fluctuations in consumer spending, intense competition from other footwear brands, and changes in fashion trends. A decline in consumer confidence or disposable income could negatively impact demand for Dr. Martens products.

What are the key factors to evaluate for DRMTY?

Evaluate DRMTY on fundamentals, analyst consensus, and risk factors. To weigh it, start with the trailing P/E under Price & valuation on this page. E-commerce Growth: The increasing popularity of online shopping presents a significant growth opportunity for Dr. Martens. Not financial advice.

How frequently does DRMTY data refresh on this page?

DRMTY's price is the last quote we recorded, from the Nov 19, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.

What has driven DRMTY's recent stock price performance?

Dr. Martens plc (DRMTY) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Strong brand recognition and heritage. See the News tab for the latest drivers. Past performance does not predict future results.

Should investors consider DRMTY overvalued or undervalued right now?

The trailing P/E of Dr. Martens plc (DRMTY) is listed under Price & valuation on this page. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.

Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 18, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 14 figures on this page — 8 from Financial Modeling Prep (FMP) and 6 with no recorded source. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.